Search
Dengue virus serotype 2
go.drugbank.com/drugs/DB22665Approved[A274008] It is one of four serotypes covered by Qdenga, a live, attenuated, tetravalent vaccine used for the prevention of dengue disease.
Dengue virus serotype 3
go.drugbank.com/drugs/DB22666Approved[A274008] It is one of four serotypes covered by Qdenga, a live, attenuated, tetravalent vaccine used for the prevention of dengue disease.
Polyvinyl alcohol
go.drugbank.com/drugs/DB11060ApprovedPolyvinyl alcohol is a water-soluble synthetic polymer obtained by polymerization of vinyl alcohol.
Tolevamer
go.drugbank.com/drugs/DB01344ApprovedIt may be taken orally or by rectum, as an enema, and functions as a potassium-binding resin in the intestines.
Somatostatin
go.drugbank.com/drugs/DB09099ApprovedInvestigationalWithdrawnIt is secreted by the D cells of the islets to inhibit the release of insulin and glucagon, and is also generated in the hypothalamus, where it inhibits the release of growth hormone and thyroid-stimulating
Chlorotoxin I-131
go.drugbank.com/drugs/DB05462InvestigationalChlorotoxin is a small 36-amino-acid peptide that selectively binds to glioma cells but not normal brain parenchyma. … The selective effects of Chlorotoxin I-131 are regulated by its action on MMP2 receptors.
Pagoclone
go.drugbank.com/drugs/DB04903InvestigationalIt is one of a relatively recently developed class of medicines known as the nonbenzodiazepines, which have similar effects to the older benzodiazepine group, but with quite different chemical structures
Velmanase alfa
go.drugbank.com/drugs/DB12374ApprovedInvestigational[L39744] It was granted marketing authorization by the European Commission in March 2018 under the market name Lamzede [L39754] as the first human recombinant form of alpha-mannosidase for the treatment
Enfortumab vedotin
go.drugbank.com/drugs/DB13007ApprovedInvestigational[L10836] Enfortumab vedotin was later approved by the European Commission on April 13, 2022.[L42000] … [L10836] It is comprised of a fully human monoclonal antibody targeted against Nectin-4 and a microtubule-disrupting chemotherapeutic agent, monomethyl auristatin E (MMAE), joined by a protease-cleavable
Duloxetine
go.drugbank.com/drugs/DB00476ApprovedInvestigational[label] It was originally discovered in 1993 and developed by Eli Lilly and Company as LY248686.